<List><item><source>MED</source><extId>28434399</extId><pmcid>PMC5402056</pmcid><annotations><annotation><prefix> OS, ORR, safety[33]</prefix><exact>NCT02259621</exact><postfix>2ALLNIVONeoadjuvant </postfix><tags><tag><name>NCT02259621</name><uri>http://identifiers.org/clinicaltrials/NCT02259621</uri></tag></tags><id>http://europepmc.org/articles/PMC5402056#europepmc-c6f872145fa8da09976537a8b32cc590</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>large phase 3 trial (n = 1,132) (</prefix><exact>NCT01450761</exact><postfix>). </postfix><tags><tag><name>NCT01450761</name><uri>http://identifiers.org/clinicaltrials/NCT01450761</uri></tag></tags><id>http://europepmc.org/articles/PMC5402056#europepmc-f26c922aa459aa9e747bb92fba7ca287</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ar PFSmORR (%)Ref </prefix><exact>NCT01450761</exact><postfix>3Ipilimumab11NRNR4.6</postfix><tags><tag><name>NCT01450761</name><uri>http://identifiers.org/clinicaltrials/NCT01450761</uri></tag></tags><id>http://europepmc.org/articles/PMC5402056#europepmc-cdc05d28f5622f82b2ffaef2cf1cb841</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>